NCT05872022Enrolling by invitation
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
Wegovy® (Semaglutide 2.4 mg) Pregnancy Registry Study: A Prospective Cohort Study to Investigate Safety Outcomes of Exposure to Wegovy During Pregnancy
Source: ClinicalTrials.gov · Last updated 14 Jan 2026
Brief summary (registry, in English)
This is an observational, prospective Wegovy (semaglutide 2.4 milligram \[mg\]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 728 (estimated)
- First submitted
- 26 Apr 2023
- Start date
- 5 Jul 2023
- Primary completion date
- 31 Oct 2032
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT05872022
What you commit to
- Study type: Observational
- Planned participants: 728
- From 5 Jul 2023 to the primary completion date, 31 Oct 2032
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation
- Unexposed to Wegovy cohort: Exposure to Wegovy or other GLP-1 RA at any time during pregnancy
Who the study is looking for
- Signed consent obtained before any study-related activities
- Female 15-50 years of age at the time of signing consent
- Currently or recently pregnant
- Resident of country included in the study
- Authorisation for her HCP(s) to provide data to the registry
- Exposed to Wegovy cohort: Exposure to at least one dose of Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition.
- Unexposed to Wegovy cohort: Have obesity or overweight with at least one weight related comorbid condition at conception
Age in the registry: 15 years to 50 years · Sex: Female
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| - Coordinator of this site? Confirm its status | Princeton | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.